BACKGROUND: Due to advances in viral design, oncolytic adenoviruses have emerged as a promising approach for treatment of breast cancer. Tumor tissue slices offer a stringent model system for preclinical evaluation of adenovirus therapies, since the slices retain a morphology and phenotype that more closely resembles the in vivo setting than cell line cultures, and this system has been shown to have utility in the evaluation of viral infectivity and replication. In this study, we evaluated the efficacy of viral infection and replication using a tropism-modified oncolytic adenovirus. METHODS: Breast tumor tissue slices were infected with a tropism-modified oncolytic adenovirus, and a wild-type adenovirus for comparison. Efficiency of infection was evaluated using fluorescent microscopy, as the viruses used have been modified to express red fluorescent protein. Replication of the viruses was evaluated with quantitative real-time polymerase chain reaction (PCR) to assay viral E4 genome copy number, a surrogate indicator for the number of virions. The breast tumor tissue slices were evaluated for the expression of CD46 expression by immunohistochemistry. RESULTS: Infection and replication of our tropism modified oncolytic virus has been observed in the breast cancer tissue slice model system and is comparative to wild-type virus. A qualitative increase in the number of cells showing red fluorescent protein (RFP) expression was observed correlating with increasing multiplicity of infection. Higher relative infectivity of the virus was observed in tumor tissue compared with normal breast tissue. Replication of the virus was demonstrated through increases in E4 copy number at 48 and 72 h after infection in human breast tumor slices. CONCLUSIONS: We have shown that a tropism modified oncolytic adenovirus can infect and replicate in breast cancer tissue slices, which may be an important preclinical indicator for its therapeutic utility.
BACKGROUND: Due to advances in viral design, oncolytic adenoviruses have emerged as a promising approach for treatment of breast cancer. Tumor tissue slices offer a stringent model system for preclinical evaluation of adenovirus therapies, since the slices retain a morphology and phenotype that more closely resembles the in vivo setting than cell line cultures, and this system has been shown to have utility in the evaluation of viral infectivity and replication. In this study, we evaluated the efficacy of viral infection and replication using a tropism-modified oncolytic adenovirus. METHODS:Breast tumor tissue slices were infected with a tropism-modified oncolytic adenovirus, and a wild-type adenovirus for comparison. Efficiency of infection was evaluated using fluorescent microscopy, as the viruses used have been modified to express red fluorescent protein. Replication of the viruses was evaluated with quantitative real-time polymerase chain reaction (PCR) to assay viral E4 genome copy number, a surrogate indicator for the number of virions. The breast tumor tissue slices were evaluated for the expression of CD46 expression by immunohistochemistry. RESULTS:Infection and replication of our tropism modified oncolytic virus has been observed in the breast cancer tissue slice model system and is comparative to wild-type virus. A qualitative increase in the number of cells showing red fluorescent protein (RFP) expression was observed correlating with increasing multiplicity of infection. Higher relative infectivity of the virus was observed in tumor tissue compared with normal breast tissue. Replication of the virus was demonstrated through increases in E4 copy number at 48 and 72 h after infection in humanbreast tumor slices. CONCLUSIONS: We have shown that a tropism modified oncolytic adenovirus can infect and replicate in breast cancer tissue slices, which may be an important preclinical indicator for its therapeutic utility.
Authors: Yosef S Haviv; Koichi Takayama; Joel N Glasgow; Jerry L Blackwell; Minghui Wang; Xiaosheng Lei; David T Curiel Journal: Mol Cancer Ther Date: 2002-03 Impact factor: 6.261
Authors: D H Sterman; J Treat; L A Litzky; K M Amin; L Coonrod; K Molnar-Kimber; A Recio; L Knox; J M Wilson; S M Albelda; L R Kaiser Journal: Hum Gene Ther Date: 1998-05-01 Impact factor: 5.695
Authors: Long P Le; Helen N Le; Igor P Dmitriev; Julia G Davydova; Tatyana Gavrikova; Seiji Yamamoto; David T Curiel; Masato Yamamoto Journal: J Natl Cancer Inst Date: 2006-02-01 Impact factor: 13.506
Authors: Tyler O Kirby; Angel Rivera; Daniel Rein; Minghui Wang; Ilya Ulasov; Martina Breidenbach; Manjula Kataram; Juan L Contreras; Carlos Krumdieck; Masato Yamamoto; Marianne G Rots; Hidde J Haisma; Ronald D Alvarez; Parameshwar J Mahasreshti; David T Curiel Journal: Clin Cancer Res Date: 2004-12-15 Impact factor: 12.531
Authors: Yosuke Kawakami; Hui Li; John T Lam; Victor Krasnykh; David T Curiel; Jerry L Blackwell Journal: Cancer Res Date: 2003-03-15 Impact factor: 12.701
Authors: C Rancourt; B E Rogers; B A Sosnowski; M Wang; A Piché; G F Pierce; R D Alvarez; G P Siegal; J T Douglas; D T Curiel Journal: Clin Cancer Res Date: 1998-10 Impact factor: 12.531
Authors: Zahra Madjd; Lindy G Durrant; Sarah E Pinder; Ian O Ellis; John Ronan; Sarah Lewis; Neil K Rushmere; Ian Spendlove Journal: Cancer Immunol Immunother Date: 2004-09-16 Impact factor: 6.968
Authors: Kishan A T Naipal; Nicole S Verkaik; Humberto Sánchez; Carolien H M van Deurzen; Michael A den Bakker; Jan H J Hoeijmakers; Roland Kanaar; Maaike P G Vreeswijk; Agnes Jager; Dik C van Gent Journal: BMC Cancer Date: 2016-02-09 Impact factor: 4.430
Authors: Sofia Abreu; Fernanda Silva; Rita Mendes; Teresa F Mendes; Marta Teixeira; Vítor E Santo; Erwin R Boghaert; Ana Félix; Catarina Brito Journal: Sci Rep Date: 2020-11-10 Impact factor: 4.379